Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus.
Journal: Expert opinion on investigational drugs
Published: May 29, 2024
Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: A randomized phase 2 clinical trial.
Journal: Journal of the American Academy of Dermatology
Published: October 19, 2023
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: September 09, 2022
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
Journal: The New England journal of medicine
Published: March 16, 2022
Biological impact of iberdomide in patients with active systemic lupus erythematosus.
Journal: Annals of the rheumatic diseases
Published: January 21, 2022
Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study.
Journal: Lupus science & medicine
Published: September 13, 2021
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
Journal: Rheumatology (Oxford, England)
Published: October 21, 2020
Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials.
Journal: ACR open rheumatology
Published: July 30, 2019
Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
Journal: Arthritis research & therapy
Published: December 12, 2018
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.
Journal: RMD open
Published: February 16, 2018
Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
Journal: Annals of the rheumatic diseases
Published: March 30, 2017
Last Updated: 09/26/2026